Bans impact Bio Techs ability to solve numerous impacts – GMO Crops Prove
Chui, Evers, & Zheng 20. Chui, Michael (Global Institute Partner at McKinsey and Comp. Leads research on the impact of information technologies and innovation on business, the economy, and society) Matthias Evers (is a senior partner in McKinsey’s Hamburg office and co-leads the firm’s global research and development work in the pharmaceutical and medical products practice., and Alice Zheng( s a consultant in the Silicon Valley office of McKinsey and Comp.). "How the bio revolution could transform the competitive landscape." McKinsey Quarterly 7 (2020). https://economicas.unsa.edu.ar/afinan/informacion_general/lecturas_recomendadas/lecturas/mckinsey_how_eng.pdf. shARK)
The rate at which biological opportunities enter the market will fluctuate sharply in response to regulatory pressures. Regional variations of regulation can have significant impact on the potential to scale and commercialize biological technologies. Companies will need to sharpen their capabilities for engaging with national and supranational agencies. Public opinion and perception can lead to regulation changes and are therefore vital factors in how the Bio Revolution proceeds. We have seen this pattern before, with the regulation of the first wave of genetically modified crops. The United States took a permissive regulatory stance, Europe put in place a near-total ban, and China recently came out somewhere in the middle by banning the farming of genetically modified crops but not the import of selected varieties of harvested genetically modified crops. Beyond general sentiment, trust is a critical factor. People must have a degree of trust in companies that propose to sequence and analyze a person’s genome, edit children’s genes, or connect to a brain–machine interface. Within consumer markets alone, as the mining of personal genetic data increases, businesses will need to understand the trade-offs between advancing commercial opportunities and protecting public and social welfare.14 For example, the data-sharing practices of some direct-to-consumer genetic-testing companies with pharma companies and app developers have been called into question by consumers and media, revealing just how precious trust is—and how easy it is to damage it with just a few poorly handled mistakes.